The United States Patent and Trademark Office (USPTO) has granted patent US12577299B2 to Surface Oncology, LLC. This patent covers novel anti-IL-27 antibodies and antigen-binding portions thereof, along with methods for treating or ameliorating symptoms of diseases, particularly cancer, through the administration of these antibodies at doses ranging from approximately 0.003 mg/kg to 20 mg/kg. The patent was filed on May 6, 2022, and granted on March 17, 2026, with 22 claims.

This patent grant signifies a new intellectual property right for Surface Oncology, LLC in the field of cancer therapeutics. While not a regulatory rule imposing obligations on other entities, it establishes exclusive rights for the patent holder. Companies operating in the oncology space, particularly those developing antibody-based therapies or researching IL-27 pathways, should be aware of this granted patent to avoid potential infringement and to inform their own R&D strategies. No immediate compliance actions are required for other entities, but awareness is crucial for competitive and legal positioning.